Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who the investigator believes can and will comply with the requirements of the protocol~* A male or female 18 years of age or older, in stable health, as established by medical history and physical examination before entering into the study.~* Written informed consent obtained from the subject.~* Access to a consistent means of telephone contact, which may be either in the home or at the workplace, land line, or mobile, but NOT a pay phone or other multiple-user device.~* Female subjects of non-childbearing potential may be enrolled in the study.~* Female subjects of childbearing potential may be enrolled in the study, if the subject:~* - has practiced adequate contraception for 30 days prior to vaccination, and~* - has a negative pregnancy test on the day of vaccination, and~* - has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series.~Exclusion Criteria:~* Use of an investigational / non-registered product other than the study vaccines within 30 days before study vaccination or planned use during study period.~* Planned administration or administration of a licensed vaccine within 30 days before study vaccination.~* Prior receipt of 2010/2011 influenza vaccine.~* Receipt of any investigational or approved influenza vaccine within six months of the first study visit.~* Any known or suspected allergy to any constituent of influenza vaccines ; a history of anaphylactic-type reaction to constituent of vaccine; or a history of severe adverse reaction to a previous influenza vaccine.~* History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccines.~* History of Guillain-Barre syndrome within 6 weeks of receipt of prior inactivated influenza virus vaccine.~* Presence or evidence of substance abuse or of neurological or psychiatric diagnoses which, even if clinically stable, are deemed by the investigator to render the potential subject unable / unlikely to provide accurate safety reports.~* Acute, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, based on history and physical examination.~* Presence of significant uncontrolled chronic medical or neuropsychiatric illness, based on history and physical examination~* Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.~* Any significant disorder of coagulation or treatment with Coumadin derivatives or heparin~* Chronic administration of immunosuppressants or other immune-modifying drugs within 3 months prior to the first vaccine/product dose.~* Administration of immunoglobulins and/or any blood products within the 3 months preceding the first dose of study vaccine or planned administration during the study period.~* Pregnant or lactating female.~* Fever at the time of enrolment.~* Acute disease at the time of enrolment~* Any other condition which, in the opinion of the Investigator, prevents the subject from participating in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- GSK2282512A 1 Group (Type: EXPERIMENTAL): Subjects received at Day 0 one dose of the GSK2282512A vaccine, Lot 1. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
- GSK2282512A 2 Group (Type: EXPERIMENTAL): Subjects received at Day 0 one dose of the GSK2282512A vaccine, Lot 2. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
- GSK2282512A 3 Group (Type: EXPERIMENTAL): Subjects received at Day 0 one dose of the GSK2282512A vaccine, Lot 3. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
- Victoria Strain FluLaval Group (Type: ACTIVE_COMPARATOR): Subjects received at Day 0 one dose of FluLaval®-VB vaccine containing the Victoria B flu strain. The FluLaval®-VB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
- Yamagata Strain FluLaval Group (Type: ACTIVE_COMPARATOR): Subjects received at Day 0 one dose of FluLaval®-YB vaccine containing the Yamagata B flu strain. The FluLaval®-YB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete